The Forgotten Search for an LSD “Antidote”

This commentary reconstructs a neglected early clinical finding in psychopharmacology: The mid-1950s clinical observation that chlorpromazine partially antagonizes the subjective effects of Lysergic acid diethylamide (LSD). Here, we provide the first English translation of the foundational 1955 study by Giberti and Gregoretti. This early work, alongside some contemporaneous and ethically abusive human experimentation funded by the Central Intelligence Agency of the federal government of the United States (CIA) under its MKULTRA program, demonstrated significant pharmacological blockade. However, this line of inquiry was severed from the scientific literature following the suppression of psychedelic research in the 1970s. Consequently, this clear drug–drug interaction remained an isolated clinical fact without a mechanistic explanation for decades. Modern neuropharmacology has now elucidated the precise receptor-level basis: Chlorpromazine acts as an antagonist at the 5-HT 2A receptor, the primary molecular target of classic psychedelics like LSD. Thus, contemporary receptor knowledge validates and explains these prescient, premechanistic clinical insights.

Authors

Institutions

Publication Details

Journal
Psychedelic Medicine
Published
2026-11-14
DOI
https://doi.org/10.1177/28314425261507297
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Forgotten Search for an LSD “Antidote”

Roberto De Filippo
Psychedelic Medicine
Psychedelics and Drug Studies
article

The Forgotten Search for an LSD “Antidote”

Roberto De Filippo
article en

Abstract

This commentary reconstructs a neglected early clinical finding in psychopharmacology: The mid-1950s clinical observation that chlorpromazine partially antagonizes the subjective effects of Lysergic acid diethylamide (LSD). Here, we provide the first English translation of the foundational 1955 study by Giberti and Gregoretti. This early work, alongside some contemporaneous and ethically abusive human experimentation funded by the Central Intelligence Agency of the federal government of the United States (CIA) under its MKULTRA program, demonstrated significant pharmacological blockade. However, this line of inquiry was severed from the scientific literature following the suppression of psychedelic research in the 1970s. Consequently, this clear drug–drug interaction remained an isolated clinical fact without a mechanistic explanation for decades. Modern neuropharmacology has now elucidated the precise receptor-level basis: Chlorpromazine acts as an antagonist at the 5-HT 2A receptor, the primary molecular target of classic psychedelics like LSD. Thus, contemporary receptor knowledge validates and explains these prescient, premechanistic clinical insights.

Psychedelic Medicine
Allen Institute (US), Bernstein Center for Computational Neuroscience Berlin (DE)
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon